Recognizing that developmental research funds are an integral part of the SPORE, we commit $175,000 per year to these endeavors. This represents a significant percent in the budget of the UMCCC Prostate SPORE and reflects the continued commitment of this program to the development of innovative translational research in prostate cancer. The focus of the Developmental Research Program is to provide investigators the ability to generate data that would become the preliminary data for an R01 grant application or an equivalent proposal. Investigators from outside the field of prostate cancer are encouraged to apply through campus wide announcements as well as through personal interactions with the SPORE investigators. We developed a stepwise proposal solicitation and review process for pilot projects utilizing a NIH-type PHS 398 format that has been streamlined for rapid turn around of research proposals and which recognizes that these projects may have little preliminary data. Investigators may apply for pilot project grants ($40,000 - $50,000 per year) or seed grants ($5,000 - $10,000 per year). Since 1995 we have funded 52 pilot projects and 61 seed grants with a total investment of $2.5 million. This has resulted in over $20 million in subsequent grants and 101 manuscripts. Dr. Maha Hussain and Dr. Mark Day serve as Co- Directors for the Developmental Research Program. Dr. Hussain is a Professor of Internal Medicine and Urology, and is nationally and internationally recognized for her scientific clinical research expertise in the area of genitourinary-oncology, particularly prostate and bladder cancers. She serves as the """"""""clinical"""""""" expert for the Research Development Program. Dr. Mark'Day is a Professor of Urology and has published extensively in the area of prostate cell biology. He serves as the """"""""basic science"""""""" mentor of the Research Development Program. Dr. Day is the PI of the Urology Training Grant and participates as a mentor in the Cancer Biology Training Grant. Drs. Hussain and Day meet twice with each project investigator to review progress. Project investigators also take part in the monthly SPORE meetings and annual retreat.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA069568-15
Application #
8375947
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
2014-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
15
Fiscal Year
2012
Total Cost
$66,241
Indirect Cost
$23,285
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Wang, Xiaoju; Qiao, Yuanyuan; Asangani, Irfan A et al. (2017) Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. Cancer Cell 31:532-548.e7
Blattner, Mirjam; Liu, Deli; Robinson, Brian D et al. (2017) SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell 31:436-451
Dai, Xiangpeng; Gan, Wenjian; Li, Xiaoning et al. (2017) Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat Med 23:1063-1071
Zheng, Yi; Sun, Yubing; Yu, Xinwei et al. (2016) Angiogenesis in Liquid Tumors: An In Vitro Assay for Leukemic-Cell-Induced Bone Marrow Angiogenesis. Adv Healthc Mater 5:1014-24
Roychowdhury, Sameek; Chinnaiyan, Arul M (2016) Translating cancer genomes and transcriptomes for precision oncology. CA Cancer J Clin 66:75-88
Lange, Ethan M; Ribado, Jessica V; Zuhlke, Kimberly A et al. (2016) Assessing the Cumulative Contribution of New and Established Common Genetic Risk Factors to Early-Onset Prostate Cancer. Cancer Epidemiol Biomarkers Prev 25:766-72
Hu, Shuhuan; Liu, Guangyu; Chen, Weiqiang et al. (2016) Multiparametric Biomechanical and Biochemical Phenotypic Profiling of Single Cancer Cells Using an Elasticity Microcytometer. Small 12:2300-11
Chen, Weiqiang; Allen, Steven G; Reka, Ajaya Kumar et al. (2016) Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristics. BMC Cancer 16:614
Van Allen, Eliezer M; Robinson, Dan; Morrissey, Colm et al. (2016) A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine. Oncotarget 7:52888-52899
Mehra, Rohit; Udager, Aaron M; Ahearn, Thomas U et al. (2016) Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. Eur Urol 70:549-552

Showing the most recent 10 out of 522 publications